Sign In
Buy PTGX
$95.41
+2.18 (+2.34%)
At Close: Jun 03, 2026
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 337%
02:55pm, Friday, 11'th Nov 2022 Zacks Investment Research
The mean of analysts' price targets for Protagonist Therapeutics (PTGX) points to a 337.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 322% as Wall Street Analysts Expect?
01:55pm, Wednesday, 05'th Oct 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 322.3% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questi
Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?
04:00pm, Friday, 23'rd Sep 2022 Zacks Investment Research
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?
01:32pm, Friday, 23'rd Sep 2022
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 302%
01:55pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
The consensus price target hints at a 301.5% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
11:15pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 15.15% and 62.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock
Novavax (NVAX) Soars 5.4%: Is Further Upside Left in the Stock?
10:11am, Monday, 18'th Jul 2022 Zacks Investment Research
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Protagonist: Too Many Red Flags
10:45am, Wednesday, 08'th Jun 2022
Protagonist has recently faced a number of mishaps. These make the stock risky.
3 Biotech Stocks to Buy Before They Boom
06:15am, Wednesday, 01'st Jun 2022
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. The post 3 Biotech Stocks to Buy Before They Boom appeared first on
A new generation of ulcerative colitis drugs is in development. Will they be blockbusters for Lilly and Pfizer?
12:58pm, Sunday, 29'th May 2022 MarketWatch
Pfizer’s promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030. Lilly’s got a drug in development, too.
Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
05:10pm, Thursday, 26'th May 2022
Enrollment completed and dosing resumed in the ongoing Phase 2 REVIVE study Resumption of rusfertide administration after suspension restored therapeutic benefits including hematocrit control, reduced
A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?
02:20pm, Thursday, 26'th May 2022
Pfizer Inc.'s PFE, +0.96% promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030 if it's approved by U.S. regulators next year.
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
08:13am, Wednesday, 11'th May 2022
Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
10:35pm, Wednesday, 04'th May 2022 Zacks Investment Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 35.82% and 33.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
08:18pm, Wednesday, 04'th May 2022
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 35.82% and 33.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc
